Skip to Content

What kind of cancer does Tecentriq treat?

Answers (1)

Official Answer by 1 Jun 2016

Tecentriq (generic name: atezolizumab) treats urothelial cancer, the most common type of bladder cancer causing about 90% of all cases. Also known as a programmed death-ligand 1 (PD-L1) blocking antibody, Roche's Tecentriq was approved on May 18, 2016 and is the first PD-L1 inhibitor approved by the FDA.

Tecentriq is in a new class of immunotherapy drugs called immune checkpoint inhibitors and works by boosting the body’s immune system to help it attack cancer cells. Immune checkpoint inhibitors may also allow the immune system to attack normal organs in the body which may lead to serious side effects, but overall these drugs are better tolerated than many of the older standard cancer treatments.

Common side effects with Tecentriq may include fatigue, loss of appetite, and nausea. Other more serious side effects may include hepatitis, inflammation in the lungs, intestines, or other organs.

Votes: +0 free discount card

Further Information

Search for questions

Still looking for answers? Try searching for what you seek or ask your own question.

Frequently Asked Questions

How does Yosprala work?

Posted 30 Nov 2016 1 answerFAQ by

How is Cuvitru administered?

Posted 30 Nov 2016 1 answerFAQ by

What is the difference between Erelzi and Enbrel?

Posted 30 Nov 2016 1 answerFAQ by

How is Troxyca ER formulated to be abuse deterrent?

Posted 30 Nov 2016 1 answerFAQ by

How long does the flu last for?

Posted 16 Dec 2016 1 answerFAQ by